MedTrace Logo

Atazanavir/r + Lamivudine Dual Therapy

NCT01599364 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2019-07-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the virological efficacy of maintenance therapy with atazanavir with ritonavir combined with lamivudine in treatment experienced HIV positive patients with full and stable virological suppression.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Atazanavir, ritonavir, lamivudine

Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal

Sponsors & Collaborators

  • Catholic University of the Sacred Heart

    lead OTHER

Principal Investigators

  • Mauro MM Moroni, MD · Università di Milano Direttore clinica Malattie infettive

  • Pierluigi PZ Zoccolotti, MD · Università di Roma La Sapienza Dipartimento di Psicologia

  • Stafano SV Vella, MD · Dipartimento del farmaco all'Istituto Superiore della Sanità

  • Roberto RC Cauda, MD · Università Cattolica del S. Cuore Policlinico Universitario A. Gemelli

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-04-30
Completion
2018-02-23

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01599364 on ClinicalTrials.gov